TY - JOUR
T1 - Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years
T2 - A prospective population-based study
AU - Wanders, Rinus
AU - Steevens, Jessie
AU - Botterweck, Anita
AU - Dingemans, Anne Marie C.
AU - Reymen, Bart
AU - Baardwijk, Angela Van
AU - Borger, Jacques
AU - Bootsma, Gerben
AU - Pitz, Cordula
AU - Lunde, Ragnar
AU - Geraedts, Wiel
AU - Lambin, Philippe
AU - De Ruysscher, Dirk
PY - 2011/12
Y1 - 2011/12
N2 - Background: There is little data on the survival of elderly patients with stage III non-small cell lung cancer (NSCLC). Methods: Patients with stage III NSCLC in the Netherlands Cancer Registry/Limburg from January 1, 2002 to December 31, 2008 were included. Findings: One thousand and two patients with stage III were diagnosed, of which 237 were 75 years or older. From 228 patients, co-morbidity scores were available. Only 33/237 patients (14.5%) had no co-morbidities, 195 (85.5%) had one or more important co-morbidities, 60 (26.3%) two or more co-morbidities, 18 (7.9%) three or more co-morbidities and 2 patients (0.9%) suffered from four co-morbidities. Forty-eight percent were treated with curative intent. No significant difference in Charlson co-morbidity, age or gender was found between patients receiving curative or palliative intent treatment. Treatment with curative intent was associated with increased overall survival (OS) compared to palliative treatment: median OS 14.2 months (9.6-18.7) versus 5.2 months (4.3-6.0), 2-year OS 35.5% versus 12.1%, for curative versus palliative treatment. Patients who received only radiotherapy with curative intent had a median OS of 11.1 months (95% confidence interval [95% CI] 6.4-15.8) and a 5-year OS of 20.3%; for sequential chemotherapy and radiotherapy, the median OS was 18.0 months (95% CI 12.2-23.7), with a 5-year OS of 14.9%. Only four patients received concurrent chemo-radiation. Interpretation:In this prospective series treating elderly patients with stage III NSCLC with curative intent was associated with significant 5-year survival rates.
AB - Background: There is little data on the survival of elderly patients with stage III non-small cell lung cancer (NSCLC). Methods: Patients with stage III NSCLC in the Netherlands Cancer Registry/Limburg from January 1, 2002 to December 31, 2008 were included. Findings: One thousand and two patients with stage III were diagnosed, of which 237 were 75 years or older. From 228 patients, co-morbidity scores were available. Only 33/237 patients (14.5%) had no co-morbidities, 195 (85.5%) had one or more important co-morbidities, 60 (26.3%) two or more co-morbidities, 18 (7.9%) three or more co-morbidities and 2 patients (0.9%) suffered from four co-morbidities. Forty-eight percent were treated with curative intent. No significant difference in Charlson co-morbidity, age or gender was found between patients receiving curative or palliative intent treatment. Treatment with curative intent was associated with increased overall survival (OS) compared to palliative treatment: median OS 14.2 months (9.6-18.7) versus 5.2 months (4.3-6.0), 2-year OS 35.5% versus 12.1%, for curative versus palliative treatment. Patients who received only radiotherapy with curative intent had a median OS of 11.1 months (95% confidence interval [95% CI] 6.4-15.8) and a 5-year OS of 20.3%; for sequential chemotherapy and radiotherapy, the median OS was 18.0 months (95% CI 12.2-23.7), with a 5-year OS of 14.9%. Only four patients received concurrent chemo-radiation. Interpretation:In this prospective series treating elderly patients with stage III NSCLC with curative intent was associated with significant 5-year survival rates.
UR - http://www.scopus.com/inward/record.url?scp=82255186389&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2011.06.023
DO - 10.1016/j.ejca.2011.06.023
M3 - Article
C2 - 21733675
AN - SCOPUS:82255186389
SN - 0959-8049
VL - 47
SP - 2691
EP - 2697
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 18
ER -
